Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384683 · ClinicalTrials.gov registry record
Endothelial Dysfunction As A Predictor Of Perioperative Outcome
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 90
- Enrollment target
NCT00384683: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00384683 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00384683 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn whether the inability of certain blood vessel cells (endothelial cells) to function properly may help researchers to predict who is at risk for complications after surgery and whether this dysfunction contributes to complications after surgery. This study will use a blood test to quantify the number of cells that are destined to become endothelial cells.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-03 |
| Est. Completion | 2019-06-05 |
What the finished NCT00384683 record still lists
NCT00384683 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00384683 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00384683 about?
NCT00384683 is a clinical study titled "Endothelial Dysfunction As A Predictor Of Perioperative Outcome". The goal of this clinical research study is to learn whether the inability of certain blood vessel cells (endothelial cells) to function properly may help researchers to predict who is at risk for complications after surgery and whether this dysfunction contributes to complications after surgery. Th...
What is the current status of trial NCT00384683?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2006-03. Estimated completion is 2019-06-05.
Who is sponsoring clinical trial NCT00384683?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia